Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Randomized, Active-Controlled, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Inventprise's 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults (18 Through 40 Years)

Next Previous
Trial Profile

A Phase 1, Multicenter, Randomized, Active-Controlled, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Inventprise's 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults (18 Through 40 Years)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IVT-25 (Primary) ; PCV 20; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Otitis media; Pneumococcal infections
  • Focus Adverse reactions; First in man
  • Sponsors Inventprise

Most Recent Events

  • 28 Aug 2023 Phase changed from phase 1/2 to phase 1. Lower age limit increased from 8 weeks to 18 years. Primary end-points for young children and infants removed. Number of treatment arms decreased from 6 to 2 by the removal of young children and infant experimental sections. Study design changed from sequential to parallel.
  • 28 Aug 2023 Status changed from recruiting to completed.
  • 10 Nov 2022 According to an Inventprise media release, satisfactory Phase 1 results will trigger Phase 2, which will evaluate the IVT PCV-25, first, in young children and then, pending satisfactory data, in infants. Phase 2 will use an authorized infant 13-valent PCV as comparator.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top